Skip to content
Cultural Foundation
Author:
RealChemistry/ BOEHRINGER INGELHEIM – oncology
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine
April 17, 2026
/C O R R E C T I O N — Boehringer Ingelheim/
April 16, 2026
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine
April 16, 2026